...
首页> 外文期刊>Clinical lung cancer >Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
【24h】

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

机译:Afatinib作为EGFR突变阳性非小细胞肺癌的老年患者的一线治疗:Lux-Lung 3,Lux-Lung 6和Lux-Lung 7试验的亚组分析

获取原文
获取原文并翻译 | 示例
           

摘要

There are limited data on the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in older patients. In these subanalyses of the LUX-Lung 3, 6, and 7 trials, the efficacy of first-line afatinib in older patients with EGFR mutation-positive non-small-cell lung cancer was consistent with the overall study populations, with no unexpected safety signals. Progression-free survival was improved versus platinum-doublet chemotherapy (LUX-Lung 3/6) or gefitinib (LUX-Lung 7).
机译:关于老年患者在老年患者中表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的疗效存在有限的数据。 在Lux-Lung 3,6和7次试验的这些细胞体中,一线AFATINIB在老本突变阳性非小细胞肺癌年龄患者中的疗效与整体研究人群一致,没有意外的安全 信号。 无进展的生存率改善了铂 - 双峰化疗(Lux-Lung 3/6)或Gefitinib(Lux-Lung 7)。

著录项

  • 来源
    《Clinical lung cancer》 |2018年第4期|共15页
  • 作者单位

    Guangdong Gen Hosp Guangdong Lung Canc Inst 106 Zhongshan Er Rd Guangzhou 510080 Guangdong;

    Massachusetts Gen Hosp Dept Thorac Oncol Boston MA 02114 USA;

    Natl Canc Ctr Div Med Oncol Singapore Singapore;

    Prince Songkla Univ Dept Internal Med Hat Yai Thailand;

    Pavlov State Med Univ Dept Thorac Oncol St Petersburg Russia;

    Sun Yat Sen Univ Collaborat Innovat Ctr Canc Med State Key Lab Oncol South China Dept Med Oncol;

    Chungbuk Natl Univ Hosp Dept Internal Med Cheongju South Korea;

    Taipei Vet Gen Hosp Dept Oncol Taipei Taiwan;

    Kanagawa Cardiovasc &

    Resp Ctr Dept Resp Med Yokohama Kanagawa Japan;

    PUCRS Sch Med Dept Internal Med Porto Alegre RS Brazil;

    Univ Duisburg Essen Univ Hosp Essen West German Canc Ctr Dept Med Oncol Essen Germany;

    McGill Univ Fac Med Oncol Montreal PQ Canada;

    Wakayama Med Univ Wakayama Wakayama Prefec Japan;

    Princess Alexandra Hosp Dept Med Oncol Brisbane Qld Australia;

    Chris OBrien Lifehouse Camperdown NSW Australia;

    Chinese Univ Hong Kong Prince Wales Hosp Hong Kong Canc Inst Dept Clin Oncol State Key Lab South;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Ingelheim Germany;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Ingelheim Germany;

    Natl Taiwan Univ Hosp Dept Oncol Taipei Taiwan;

    Univ Complutense Hosp Univ Doce Octubre Dept Lung Canc CiberOnc Madrid Spain;

    Sungkyunkwan Univ Samsung Med Ctr Sch Med Div Hematol Oncol Seoul South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    EGFR blocker; Elderly; Gefitinib; NSCLC; Tyrosine kinase inhibitor;

    机译:EGFR阻止;老年人;吉替尼;NSCLC;酪氨酸激酶抑制剂;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号